Immune Therapeutics, Inc. (IMUN)
Chart Events
Performance Outlook
| Previous Close | 1.7500 |
| Open | 1.6500 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's Range | 1.6500 - 1.6500 |
| 52 Week Range | 1.0200 - 5.3500 |
| Volume | |
| Avg. Volume | 251 |
| Market Cap | 795,144 |
| Beta (5Y Monthly) | 1.01 |
| PE Ratio (TTM) | 0.29 |
| EPS (TTM) | 5.7020 |
| Earnings Date | Jun 29, 2020 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- GlobeNewswire
Immune Therapeutics Appoints Chief Financial Officer and Chief Operating Officer
ORLANDO, FL, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Immune Therapeutics, Inc. (OTC PINK:IMUN) (“Immune” or “IMUN”), a specialty pharmaceutical company involved in the acquisition, development, and commercialization of pharmaceutical and biotechnology products that have a short and well-defined path to market, is pleased to announce the appointment of Glen Farmer as Chief Financial Officer and Kelly Wilson as Chief Operating Officer. Mr. Farmer will be replacing Dr. Stephen Wilson who was serving as t
- GlobeNewswire
Immune Therapeutics, Inc. Appoints Dr. Stephen Wilson as Chief Executive Officer
ORLANDO, FL, July 22, 2022 (GLOBE NEWSWIRE) -- Immune Therapeutics, Inc. (OTC Pink: IMUN) (“Immune” or “IMUN”), a specialty pharmaceutical company involved in the acquisition, development and commercialization of pharmaceutical and biotechnology products that have a short and well-defined path to market, is pleased to announce the appointment of Dr. Stephen “Steve” Wilson as Immune’s Chief Executive Officer (CEO), President, and interim Chief Financial Officer (CFO) effective July 19, 2022; he w
- GlobeNewswire
Immune Therapeutics, Inc. Announces Expansion of its Board of Directors
ORLANDO, Fla, June 03, 2022 (GLOBE NEWSWIRE) -- Immune Therapeutics, Inc. (OTC:BB IMUN), a specialty pharmaceutical company involved in the development, commercialization, distribution and marketing of novel, patented therapies to combat chronic, life-threatening diseases through the activation and modulation of the body’s immune system, today announced that it will expand its Board of Directors from two to five members. Joining the Board effective May 31st, 2022, will be Dr. Stephen Wilson, Dr.
